Back to Search
Start Over
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
- Source :
- Molecular Cell, 68(1), 210. Cell Press, Molecular Cell, Molecular Cell, 68(1), 210-223.e6. Cell Press, Molecular cell, vol 68, iss 1
-
Abstract
- Summary Chemical libraries paired with phenotypic screens can now readily identify compounds with therapeutic potential. A central limitation to exploiting these compounds, however, has been in identifying their relevant cellular targets. Here, we present a two-tiered CRISPR-mediated chemical-genetic strategy for target identification: combined genome-wide knockdown and overexpression screening as well as focused, comparative chemical-genetic profiling. Application of these strategies to rigosertib, a drug in phase 3 clinical trials for high-risk myelodysplastic syndrome whose molecular target had remained controversial, pointed singularly to microtubules as rigosertib’s target. We showed that rigosertib indeed directly binds to and destabilizes microtubules using cell biological, in vitro, and structural approaches. Finally, expression of tubulin with a structure-guided mutation in the rigosertib-binding pocket conferred resistance to rigosertib, establishing that rigosertib kills cancer cells by destabilizing microtubules. These results demonstrate the power of our chemical-genetic screening strategies for pinpointing the physiologically relevant targets of chemical agents.<br />Graphical Abstract<br />Highlights • Combined CRISPRi/a chemical-genetic screening reveals targets of therapeutic agents • Focused chemical-genetic profiling rapidly classifies agents by mechanism of action • Chemical-genetic screens with rigosertib reveal a microtubule-destabilizing signature • Targeted in vivo and in vitro approaches confirm rigosertib’s mechanism of action<br />Jost et al. present a two-tiered strategy to identify molecular targets of bioactive compounds using CRISPRi/a-mediated chemical-genetic screens. Application to rigosertib, an anti-cancer drug with an unclear mechanism of action, points to rigosertib being a microtubule-destabilizing agent. Targeted cell biological, biochemical, and structural approaches confirm this mechanism of action.
- Subjects :
- 0301 basic medicine
Drug Resistance
Kinesins
Medical and Health Sciences
Microtubules
Tubulin
2.1 Biological and endogenous factors
RNA, Guide
Sulfones
Kinetoplastida
Aetiology
Cancer
Genetics
Gene knockdown
rigosertib
Rigosertib
Kinesin
Biological Sciences
drug mechanism of action
Tubulin Modulators
3. Good health
Gene Expression Regulation, Neoplastic
chemical genetics
5.1 Pharmaceuticals
Development of treatments and therapeutic interventions
Chemical genetics
RNA, Guide, Kinetoplastida
Biotechnology
Recombinant Fusion Proteins
Genetic Vectors
Glycine
Antineoplastic Agents
Computational biology
Biology
Vinblastine
Article
Small Molecule Libraries
microtubules
03 medical and health sciences
CRISPRa
Rare Diseases
Microtubule
Journal Article
Humans
Genetic Testing
Molecular Biology
drug target identification
Neoplastic
Human Genome
Lentivirus
CRISPRi
Cell Biology
genome-wide CRISPR screening
Orphan Drug
030104 developmental biology
Gene Expression Regulation
Drug Resistance, Neoplasm
Myelodysplastic Syndromes
Mutation
biology.protein
Neoplasm
RNA
CRISPR-Cas Systems
Colchicine
K562 Cells
Guide
Developmental Biology
HeLa Cells
Genetic screen
Subjects
Details
- Language :
- English
- ISSN :
- 10972765
- Volume :
- 68
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Molecular Cell
- Accession number :
- edsair.doi.dedup.....f179af91573489aafc58613822af4048
- Full Text :
- https://doi.org/10.1016/j.molcel.2017.09.012